A Trial Investigating the Efficacy and Safety of NVG-291 in Subjects With Chronic Spinal Cord Injury
← catalyst calendarNCT07799532 · readout in 314 d
Sponsored by NervGen Pharma (industry) · NGEN — their whole pipeline →.
Phase
Phase 3
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
150estimated
Sites
18
Countries
Canada, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-09-02
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-09-23 | estimated | When the study began enrolling |
| Primary completion | 2027-07-14 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-12-14 | estimated | The whole study's end, after follow-up |
| First posted | 2026-09-02 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-09-02 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Chronic Spinal Cord Injury
Interventions
- Drug: NVG-291
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFEfficacy of NVG-291 as measured by change from baseline in combined Graded and Redefined Assessment of Strength, Sensibility and Prehension (GRASSP) Quantitative Prehension (QtP) score
measured Baseline to Week 12
Related
NGEN's other studiesmost recently updated first
- NVG-291 in Spinal Cord Injury Subjects Phase 1/2 · Completed
- A Phase I Safety Study of NVG-291 in Healthy Adults Phase 1 · Completed
Permalink · NGEN's whole pipeline · Catalyst calendar · Every registered study · What changed